Genetic Technologies EPS - Earnings per Share 2010-2021 | GENE
Genetic Technologies eps - earnings per share from 2010 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Genetic Technologies Annual EPS |
| 2021 |
$-0.36 |
| 2020 |
$-0.60 |
| 2019 |
$-1.05 |
| 2018 |
$-1.02 |
| 2017 |
$-1.79 |
| 2016 |
$-2.16 |
| 2015 |
$-4.12 |
| 2014 |
$-9.60 |
| 2013 |
$-12.20 |
| 2012 |
$-7.20 |
| 2011 |
$1.40 |
| 2010 |
$-13.00 |
| 2009 |
$-0.20 |
| Genetic Technologies Quarterly EPS |
| 2021-12-31 |
$0.00 |
| 2021-06-30 |
$0.00 |
| 2020-12-31 |
$0.00 |
| 2020-06-30 |
$0.00 |
| 2019-12-31 |
$0.00 |
| 2019-06-30 |
$0.00 |
| 2018-12-31 |
$0.00 |
| 2018-06-30 |
$0.00 |
| 2017-12-31 |
$0.00 |
| 2017-06-30 |
$0.00 |
| 2016-12-31 |
$0.00 |
| 2016-06-30 |
$0.00 |
| 2015-12-31 |
$0.00 |
| 2015-06-30 |
$0.00 |
| 2014-12-31 |
$0.00 |
| 2014-06-30 |
$0.00 |
| 2013-12-31 |
$0.00 |
| 2013-06-30 |
$0.00 |
| 2012-12-31 |
$0.00 |
| 2012-06-30 |
$0.00 |
| 2011-12-31 |
$0.00 |
| 2011-06-30 |
$0.00 |
| 2010-12-31 |
$0.00 |
| 2010-06-30 |
$0.00 |
| 2009-12-31 |
$0.00 |
| 2009-06-30 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.020B |
$0.000B |
|
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
|
